[Blood platelets and cardiovascular diseases. IV. Platelet-inhibiting drugs and antithrombotic agents].
D000244:Adenosine Diphosphate / Q000378:metabolism; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000700:Analgesics / Q000494:pharmacology; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D001161:Arteriosclerosis / Q000188:drug therapy; D001241:Aspirin / Q000494:pharmacology; D001777:Blood Coagulation; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D002318:Cardiovascular Diseases / Q000209:etiology*; D004176:Dipyridamole / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D007213:Indomethacin / Q000494:pharmacology; D010113:Oxyphenbutazone / Q000494:pharmacology; D010653:Phenylbutazone / Q000494:pharmacology; D010973:Platelet Adhesiveness; D010974:Platelet Aggregation / Q000187:drug effects; D013442:Sulfinpyrazone / Q000494:pharmacology; D013923:Thromboembolism / Q000517:prevention & control; D013997:Time Factors
D000319:Adrenergic beta-Antagonists; D000700:Analgesics; D000893:Anti-Inflammatory Agents; D005343:Fibrinolytic Agents; D000244:Adenosine Diphosphate; D004176:Dipyridamole; D010653:Phenylbutazone; D010113:Oxyphenbutazone; D001241:Aspirin; D013442:Sulfinpyrazone; D007213:Indomethacin
Plaquettes sanguines et maladies cardiovasculaires. IV. Médicaments inhibant les plaquettes et antithrombotiques